[go: up one dir, main page]

AR099753A1 - Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro - Google Patents

Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Info

Publication number
AR099753A1
AR099753A1 ARP150100765A ARP150100765A AR099753A1 AR 099753 A1 AR099753 A1 AR 099753A1 AR P150100765 A ARP150100765 A AR P150100765A AR P150100765 A ARP150100765 A AR P150100765A AR 099753 A1 AR099753 A1 AR 099753A1
Authority
AR
Argentina
Prior art keywords
composition
coagulation control
abnormal coagulation
vitro tests
control plasma
Prior art date
Application number
ARP150100765A
Other languages
English (en)
Inventor
Martorell Pena Daniel
Segui Borrell Jose
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of AR099753A1 publication Critical patent/AR099753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro, comprendiendo dicha composición: plasma humano, solución isotónica tamponada y ácido ferúlico, caracterizada porque dicho plasma humano se ha obtenido mediante métodos conocidos de extracción de plasma humano y porque dicha solución isotónica tamponada tiene un pH entre 6,5 y 8,5. Reivindicación 11: Uso de ácido ferúlico en la preparación de un control anormal de la coagulación en ensayos in vitro.
ARP150100765A 2014-03-13 2015-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro AR099753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430343A ES2475492B1 (es) 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Publications (1)

Publication Number Publication Date
AR099753A1 true AR099753A1 (es) 2016-08-17

Family

ID=51063211

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100765A AR099753A1 (es) 2014-03-13 2015-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Country Status (11)

Country Link
US (1) US9482679B2 (es)
EP (1) EP2919014B1 (es)
JP (1) JP6215245B2 (es)
CN (1) CN104914256B (es)
AR (1) AR099753A1 (es)
AU (1) AU2015201260B2 (es)
BR (1) BR102015005628A8 (es)
CA (1) CA2883260C (es)
CL (1) CL2015000469A1 (es)
ES (2) ES2475492B1 (es)
MX (1) MX362870B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108169467B (zh) * 2017-11-27 2019-09-20 中国科学院苏州生物医学工程技术研究所 一种血栓弹力图仪质控品及其制备方法和应用
CN109239373A (zh) * 2018-08-15 2019-01-18 迪瑞医疗科技股份有限公司 一种组织因子酯化物试剂及其制备方法与应用
CN110346582B (zh) * 2019-07-15 2022-10-25 三诺生物传感股份有限公司 一种凝血复合质控品及其制备方法
CN119780450B (zh) * 2025-03-11 2025-07-04 成都协和生物技术有限责任公司 一种凝血七项复合质控品及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
AU7137900A (en) * 1999-07-23 2001-02-13 Medical Analysis Systems, Inc. Stabilized coagulation control reagent and method of making same
CN103626653B (zh) * 2013-08-14 2015-06-24 河南大学 冬凌草促凝血有效成分及其制备方法和应用

Also Published As

Publication number Publication date
BR102015005628A2 (pt) 2016-04-26
CN104914256A (zh) 2015-09-16
JP2015175850A (ja) 2015-10-05
MX2015003192A (es) 2015-10-29
EP2919014A1 (en) 2015-09-16
EP2919014B1 (en) 2017-08-16
ES2475492B1 (es) 2015-01-15
MX362870B (es) 2019-02-20
CA2883260A1 (en) 2015-09-13
AU2015201260B2 (en) 2018-05-10
ES2475492A1 (es) 2014-07-10
US9482679B2 (en) 2016-11-01
ES2639445T3 (es) 2017-10-26
CL2015000469A1 (es) 2015-10-02
BR102015005628A8 (pt) 2022-07-05
AU2015201260A1 (en) 2015-10-01
JP6215245B2 (ja) 2017-10-18
CN104914256B (zh) 2018-04-03
CA2883260C (en) 2019-02-19
US20150260740A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
CL2018000194A1 (es) Compuestos de piridina
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UY34697A (es) Métodos para preparar análogos de nucleótidos
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2017012206A (es) Proliferacion ex vivo de celulas epiteliales.
UY34763A (es) Inhibidores de la agregación plaquetaria
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
AR095233A1 (es) Métodos y composiciones para el control de malezas
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
MX2015003140A (es) Formulaciones de enzalutamida.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
MX2017002469A (es) Composiciones de matrices extracelulares.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2018000756A1 (es) Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
MX376945B (es) Proceso novedoso para la preparación de pirrolidina-dionas espiroheterocíclicas.
AR099753A1 (es) Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
MX387903B (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.

Legal Events

Date Code Title Description
FG Grant, registration